TY - JOUR
T1 - Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes
T2 - Animal models and clinical findings
AU - Dichter, Gabriel S.
AU - Damiano, Cara A.
AU - Allen, John A.
N1 - Funding Information:
We are grateful for helpful discussions with James W. Bodfish, C.J. Malanga, Joseph Piven, and the comments of two anonymous reviewers. Preparation of this manuscript was supported by K23 MH081285 (GSD), R01 MH073402 (GSD), and by a Weatherstone Predoctoral Fellowship from Autism Speaks (#7413) (CAD).
PY - 2012
Y1 - 2012
N2 - This review summarizes evidence of dysregulated reward circuitry function in a range of neurodevelopmental and psychiatric disorders and genetic syndromes. First, the contribution of identifying a core mechanistic process across disparate disorders to disease classification is discussed, followed by a review of the neurobiology of reward circuitry. We next consider pre-clinical animal models and clinical evidence of reward-pathway dysfunction in a range of disorders, including psychiatric disorders (i.e., substance-use disorders, affective disorders, eating disorders, and obsessive compulsive disorders), neurodevelopmental disorders (i.e., schizophrenia, attention-deficit/hyperactivity disorder, autism spectrum disorders, Tourette's syndrome, conduct disorder/oppositional defiant disorder), and genetic syndromes (i.e., Fragile X syndrome, Prader-Willi syndrome, Williams syndrome, Angelman syndrome, and Rett syndrome). We also provide brief overviews of effective psychopharmacologic agents that have an effect on the dopamine system in these disorders. This review concludes with methodological considerations for future research designed to more clearly probe rewardcircuitry dysfunction, with the ultimate goal of improved intervention strategies.
AB - This review summarizes evidence of dysregulated reward circuitry function in a range of neurodevelopmental and psychiatric disorders and genetic syndromes. First, the contribution of identifying a core mechanistic process across disparate disorders to disease classification is discussed, followed by a review of the neurobiology of reward circuitry. We next consider pre-clinical animal models and clinical evidence of reward-pathway dysfunction in a range of disorders, including psychiatric disorders (i.e., substance-use disorders, affective disorders, eating disorders, and obsessive compulsive disorders), neurodevelopmental disorders (i.e., schizophrenia, attention-deficit/hyperactivity disorder, autism spectrum disorders, Tourette's syndrome, conduct disorder/oppositional defiant disorder), and genetic syndromes (i.e., Fragile X syndrome, Prader-Willi syndrome, Williams syndrome, Angelman syndrome, and Rett syndrome). We also provide brief overviews of effective psychopharmacologic agents that have an effect on the dopamine system in these disorders. This review concludes with methodological considerations for future research designed to more clearly probe rewardcircuitry dysfunction, with the ultimate goal of improved intervention strategies.
KW - Dopamine
KW - Mesolimbic
KW - Neuroimaging
KW - Nucleus Accumbens
KW - Reward
KW - Striatum
UR - http://www.scopus.com/inward/record.url?scp=84863962552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863962552&partnerID=8YFLogxK
U2 - 10.1186/1866-1955-4-19
DO - 10.1186/1866-1955-4-19
M3 - Review article
C2 - 22958744
AN - SCOPUS:84863962552
SN - 1866-1947
VL - 4
JO - Journal of Neurodevelopmental Disorders
JF - Journal of Neurodevelopmental Disorders
IS - 1
ER -